Addex Therapeutics
ADXN
3 hedge funds and large institutions have $717K invested in Addex Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
15% more capital invested
Capital invested by funds: $625K → $717K (+$91.7K)
9.57% more ownership
Funds ownership: 4.7% → 14.27% (+9.6%)
40% less funds holding
Funds holding: 5 → 3 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$101K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$6.58K |
| 2 |
Jane Street
New York
|
-$4.07K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$28 |
ADXN Hedge Fund Activity: Q4 2023 in Review
3 of the 6,871 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q4 2023, worth a combined $717K — up 15% from $625K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ADXN and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Armistice Capital, adding an estimated $101K. The largest seller was Baader Bank Aktiengesellschaft, exiting entirely with an estimated $6.58K sold.
- 3 institutional investors held Addex Therapeutics (ADXN) as of Q4 2023, down from 5 in Q3 2023.
- Funds reported $717K of Addex Therapeutics stock for Q4 2023, up 15% quarter-over-quarter.
- 1 fund opened new Addex Therapeutics positions in Q4 2023 and 3 closed out, a net change of -2 holders.
- The largest Addex Therapeutics buyer in Q4 2023 was Armistice Capital, an estimated $101K added.
- The largest Addex Therapeutics seller in Q4 2023 was Baader Bank Aktiengesellschaft, an estimated $6.58K sold.
Based on aggregated 13F filings for Q4 2023.